Postoperative Bleeding Risk after Gastric Endoscopic Submucosal Dissection in Patients Receiving a P2Y12 Receptor Antagonist
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The safety of gastric endoscopic submucosal dissection (ESD) in users of a P2Y12 receptor antagonist (P2Y12RA) under current guidelines has not been verified. Methods: Patients treated by gastric ESD at Okayama University Hospital between January 2013 and December 2020 were registered. The postoperative bleeding rates of patients (group A) who did not receive any antithrombotic drugs; patients (group B) receiving aspirin or cilostazol monotherapy; and P2Y12RA users (group C) those on including monotherapy or dual antiplatelet therapy were compared. The risk factors for post-ESD bleeding were examined in a multivariate analysis of patient background, tumor factors, and antithrombotic drug management. Results: Ultimately, 1,036 lesions (847 patients) were enrolled. The bleeding rates of group B and C were significantly higher than that of group A (p=0.012 and p<0.001, respectively), but there was no significant difference between group B and C (p=0.11). The postoperative bleeding rate was significantly higher in dual antiplatelet therapy than in P2Y12RA monotherapy (p=0.014). In multivariate analysis, tumor diameter ≥12 mm (odds ratio [OR], 4.30; 95% confidence interval [CI], 1.99 to 9.31), anticoagulant use (OR, 4.03; 95% CI, 1.64 to 9.86), and P2Y12RA use (OR, 3.40; 95% CI, 1.07 to 10.70) were significant risk factors for postoperative bleeding. Conclusions: P2Y12RA use is a risk factor for postoperative bleeding in patients who undergo ESD even if receiving drug management according to guidelines. Dual antiplatelet therapy carries a higher risk of bleeding than monotherapy.
Abstract
Background/Aims: The safety of gastric endoscopic submucosal dissection (ESD) in users of a P2Y12 receptor antagonist (P2Y12RA) under current guidelines has not been verified. Methods: Patients treated by gastric ESD at Okayama University Hospital between January 2013 and December 2020 were registered. The postoperative bleeding rates of patients (group A) who did not receive any antithrombotic drugs; patients (group B) receiving aspirin or cilostazol monotherapy; and P2Y12RA users (group C) those on including monotherapy or dual antiplatelet therapy were compared. The risk factors for post-ESD bleeding were examined in a multivariate analysis of patient background, tumor factors, and antithrombotic drug management. Results: Ultimately, 1,036 lesions (847 patients) were enrolled. The bleeding rates of group B and C were significantly higher than that of group A (p=0.012 and p<0.001, respectively), but there was no significant difference between group B and C (p=0.11). The postoperative bleeding rate was significantly higher in dual antiplatelet therapy than in P2Y12RA monotherapy (p=0.014). In multivariate analysis, tumor diameter ≥12 mm (odds ratio [OR], 4.30; 95% confidence interval [CI], 1.99 to 9.31), anticoagulant use (OR, 4.03; 95% CI, 1.64 to 9.86), and P2Y12RA use (OR, 3.40; 95% CI, 1.07 to 10.70) were significant risk factors for postoperative bleeding. Conclusions: P2Y12RA use is a risk factor for postoperative bleeding in patients who undergo ESD even if receiving drug management according to guidelines. Dual antiplatelet therapy carries a higher risk of bleeding than monotherapy.
참고문헌 (22)
- Oda I, "A multicenter retrospective study of endoscopic resection for early gastric cancer", Gastric Cancer, 9, pp.262~270 (2006)
- Lian J, "A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer", Gastrointest Endosc, 76, pp.763~770 (2012)
- Park YM, "The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer : a systematic review and metaanalysis", Surg Endosc, 25, pp.2666~2677 (2011)
- Itaru Saito, "Complications Related to Gastric Endoscopic Submucosal Dissection and Their Managements", Clinical Endoscopy, 47(5), pp.398~403 (2014), 대한소화기내시경학회
- Miyahara K, "Perforation and postoperative bleeding of endoscopic submucosal dissection in gastric tumors : analysis of 1190 lesions in low-and highvolume centers in Saga, Japan", Digestion, 86, pp.273~280 (2012)
- Toyokawa T, "Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms : analysis of 1123 lesions", J Gastroenterol Hepatol, 27, pp.907~912 (2012)
- Yano T, "Different clinical characteristics associated with acute bleeding and delayed bleeding after endoscopic submucosal dissection in patients with early gastric cancer", Surg Endosc, 31, pp.4542~4550 (2017)
- Takeuchi T, "The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection", BMC Gastroenterol, 13, pp.136~ (2013)
- Fujimoto K, "Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment", Dig Endosc, 26, pp.1~14 (2014)
- Singh M, "Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy", Gastrointest Endosc, 71, pp.998~1005 (2010)
- Lim JH, "Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms?", Gastrointest Endosc, 75, pp.719~727 (2012)
- Mochizuki S, "Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms(the SAFE trial) : a multicentre prospective randomised controlled non-inferiority trial", Gut, 64, pp.397~405 (2015)
- Tounou S, "Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy", Endosc Int Open, 3, pp.E31~E38 (2015)
- Furuhata T, "Postoperative bleeding after gastric endoscopic submucosal dissection in patients receiving antithrombotic therapy", Gastric Cancer, 20, pp.207~214 (2017)
- Kono Y, "Postoperative bleeding risk after gastric endoscopic submucosal dissection during antithrombotic drug therapy", J Gastroenterol Hepatol, 33, pp.453~460 (2018)
- Sooyeon Oh, "Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tum", Gut and Liver, 12(4), pp.393~401 (2018), 거트앤리버 소화기연관학회협의회
- Igarashi K, "Should antithrombotic therapy be stopped in patients undergoing gastric endoscopic submucosal dissection?", Surg Endosc, 31, pp.1746~1753 (2017)
- Hatta W, "Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer : BEST-J score", Gut, 70, pp.476~484 (2021)
- Ono S, "Thienopyridine derivatives as risk factors for bleeding following high risk endoscopic treatments : Safe Treatment on Antiplatelets(STRAP)study", Endoscopy, 47, pp.632~637 (2015)
- Numasawa Y, "Incidence and predictors of bleeding complications after percutaneous coronary intervention", J Cardiol, 69, pp.272~279 (2017)
- Mehran R, "Ticagrelor with or without aspirin in high-risk patients after PCI", N Engl J Med, 381, pp.2032~2042 (2019)
- Nakamura M, "JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease", Circ J, 84, pp.831~865 (2020)